Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: Results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers

Journal of Clinical Pharmacology

Volumn 52, Issue 7, 2012, Pages 1007-1016

  Naik, Himanshu ^a   Vakilynejad, Majid ^a   Wu, Jingtao ^a   Viswanathan, Prabhakar ^a   Dote, Nobuhito ^b   Higuchi, Tomoaki ^b   Leifke, Eckhard ^a  

^a TAKEDA PHARMACEUTICALS   (United States)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

diabetes; GPR40 agonist; pharmacodynamic; pharmacokinetic; TAK 875

Indexed keywords

6 [[2',6' DIMETHYL 4' [3 (METHYLSULFONYL) PROPOXY)BIPHENYL 3YL]METHOXY] 2,3 DIHYDRO 1 BENZOFURAN 3 YL]ACETIC ACID HYDRATE; ACETIC ACID DERIVATIVE; ANTIDIABETIC AGENT; C PEPTIDE; G PROTEIN COUPLED RECEPTOR 40; GLUCOSE; INSULIN; PLACEBO; TAK 875; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE; VOLUNTEER;

ADOLESCENT; ADULT; AREA UNDER CURVE; BENZOFURANS; BLOOD GLUCOSE; C-PEPTIDE; DIETARY FATS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; INSULIN; MALE; MIDDLE AGED; RECEPTORS, G-PROTEIN-COUPLED; SULFONES; YOUNG ADULT;

EID: 84863208301     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011409230     Document Type: Article

References (21)

1. International Diabetes Federation. IDF Diabetes Atlas. http:// www.diabetesatlas.org/content/diabetes-and-impaired-glucose-olerance. Accessed August 6, 2010.
2. National Institutes of Health. National Diabetes Statistics, 2007. June 2008. NIH Publication No. 08-3892. http://diabetes.niddk.nih .gov/dm/pubs/statistics/index.htm. Accessed August 6, 2010.
3. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799-806. (Pubitemid 34000783)
4. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: sulfonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabetes Med. 1998;15:297-303.
5. Alquier T, Poitout V. GPR40: good cop, bad cop? Diabetes. 2009;58:1035-1036.
6. Stoddart LA, Smith NJ, Milligan G. International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol Rev. 2008;60:405-417.
7. Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature. 2003;422:173-176. (Pubitemid 36362750)
8. Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Rorsman P. A selective GPR40 agonist, TAK-875, augments glucose-dependent insulin secretion without affecting glucagon secretion in isolated rat and human islets (oral presentation). Presented at: 46th Annual Meeting of the European Association for the Study of Diabetes; September 20-24, 2010; Stockholm, Sweden.
9. Edfalk S, Steneberg P, Edlund H. GPR40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes. 2008;57:2280-2287.
10. Morgan NG, Dhayal S. G-protein coupled receptors mediating long chain fatty acid signalling in the pancreatic beta-cell. Biochem Pharmacol. 2009;78:1419-1427.
11. Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab. 2005;1:245-258. (Pubitemid 43960613)
12. Briscoe CP, Tadayyon M, Andrews JL, et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem. 2003;278:11303-11311. (Pubitemid 36792687)
13. Negoro N, Sasaki S, Mikami S, et al. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist [letter]. ACS Med Chem Lett. 2010;1:290-294.
14. Tsujihata Y, Itou R, Suzuki M, et al. TAK-875, a novel, orally available GPR40 agonist, augments glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats [abstract]. Diabetes. 2010:59(Suppl 1):A165.
15. Vakily M, Wu J, Viswanathan P, Leifke E. A safety, tolerability, pharmacokinetics, and pharmacodynamics and preliminary food-effect study of TAK-875, GPR40 agonist, following oral administration of sequential ascending single doses to healthy subjects [abstract]. Diabetes. 2010:59(Suppl 1):A172.
16. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies. Rockville, MD: FDA; 2002. http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/ UCM126833.pdf. Accessed August 6, 2010.
17. Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17:1278-1283.
18. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care. 2010:33(suppl 1):S11-S61.
19. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes. U.K. Prospective Diabetes Study 74. Diabetes. 2006; 55:1832-1839. (Pubitemid 44324140)
20. Schnell S, Schaefer M, Schöfl C. Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40. Mol Cell Endocrinol. 2007;263:173-180. (Pubitemid 44834553)
21. Fujiwara K, Maekawa F, Yada T. Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet beta-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release. Am J Physiol Endocrinol Metab. 2005;289:E670-E677. (Pubitemid 41356090)